skip to the content

Lymphoblastic lymphoma

LLs are rare tumours accounting for approximately 2% of all NHLs. More than 85-90% of adult LLs are of T-cell lineage. The leukaemic presentation is most common in children, with predominantly nodal or extranodal infiltration most common in adolescents and young men. Patients commonly present with a rapidly expanding mediastinal tumour. LLs account for less than 5% of adult lymphomas, but over 40% of childhood lymphomas.

T-cell LL tumours comprise lymphoblasts, which are slightly larger than small lymphocytes, with a round nucleus, delicate chromatin, nearly invisible nucleoli and scanty basophilic cytoplasm. The tumour cells have a T-cell phenotype (CD7+, CD3+) and are variably positive for the other T-cell antigens. T-cell receptor gene rearrangement is sometimes observed, but immunoglobulin heavy chain rearrangement is infrequent1.

Lymphoblastic lymphoma

References

  1. Sweetenham J, & Borowiz M. In: Non-Hodgkin's lymphomas. Mauch P, Armitage J, Coiffier B, Dalla-Favera R, Harris N, ed. Lippincott Williams & Wilkins 2004:503-13.

    Print

 

Your feedback is valuable to MabThera

Tell a friend

Share your knowledge with your colleagues

Recommend this website

Safety

Safety

MabThera has more than 10 years of clinical experience and more than 1,000,000 patients have been treated to date.

Find out more

MabThera in rheumatoid arthritis

MabThera in rheumatoid arthritis

Please visit this site for information on MabThera for the treatment of rheumatoid arthritis

Visit now

MabThera product characteristics

MabThera product characteristics

Find out more about the characteristics of MabThera and how it is used in the treatment of non-Hodgkin's lymphoma.

Read more